Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are becoming increasingly popular in Vietnam as the country is experiencing a rise in respiratory diseases.
Customer preferences: Vietnam has a high rate of smoking, which has led to a rise in respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. As a result, there is a growing demand for bronchodilator drugs in the country. Additionally, the aging population is also contributing to the demand for these drugs as the elderly are more prone to respiratory diseases.
Trends in the market: The bronchodilator drugs market in Vietnam is expected to grow due to the increasing prevalence of respiratory diseases. The demand for combination bronchodilator drugs is also increasing as they provide better treatment outcomes for patients with severe respiratory diseases. The market is expected to be dominated by short-acting beta-agonists (SABAs) and long-acting beta-agonists (LABAs), which are the most commonly prescribed bronchodilator drugs.
Local special circumstances: Vietnam has a developing healthcare system, which means that many people do not have access to quality healthcare. As a result, self-medication is common, and many people purchase drugs without a prescription. This has led to a rise in counterfeit drugs, which can be dangerous for patients. The government is taking steps to combat this issue by increasing regulations and cracking down on illegal drug sales.
Underlying macroeconomic factors: Vietnam has a growing economy, which has led to an increase in disposable income. This means that people are more willing to spend money on healthcare, including medication for respiratory diseases. Additionally, the government is investing in healthcare infrastructure and increasing healthcare spending, which will improve access to quality healthcare for the population. However, the high cost of imported drugs is a challenge for the market, and local manufacturers are working to develop affordable alternatives.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
